|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9633
|
|
pubmed:dateCreated |
2008-7-14
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:DummerReinhardR,
pubmed-author:EORTC Melanoma Group,
pubmed-author:EggermontAlexander M MAM,
pubmed-author:GoreMartinM,
pubmed-author:HauschildAxelA,
pubmed-author:KeilholzUlrichU,
pubmed-author:KruitWim H JWH,
pubmed-author:KusicZvonkoZ,
pubmed-author:MackieRonaR,
pubmed-author:MarsdenJeremyJ,
pubmed-author:MusatElenaE,
pubmed-author:PuntCornelis J ACJ,
pubmed-author:SalèsFrançoisF,
pubmed-author:SantinamiMarioM,
pubmed-author:SpatzAlainA,
pubmed-author:SuciuStefanS,
pubmed-author:TestoriAlessandroA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
12
|
|
pubmed:volume |
372
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
117-26
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18620949-Adolescent,
pubmed-meshheading:18620949-Adult,
pubmed-meshheading:18620949-Aged,
pubmed-meshheading:18620949-Antiviral Agents,
pubmed-meshheading:18620949-Chemotherapy, Adjuvant,
pubmed-meshheading:18620949-Disease-Free Survival,
pubmed-meshheading:18620949-Female,
pubmed-meshheading:18620949-Humans,
pubmed-meshheading:18620949-Interferon-alpha,
pubmed-meshheading:18620949-Male,
pubmed-meshheading:18620949-Melanoma,
pubmed-meshheading:18620949-Middle Aged,
pubmed-meshheading:18620949-Neoplasm Metastasis,
pubmed-meshheading:18620949-Observation,
pubmed-meshheading:18620949-Polyethylene Glycols,
pubmed-meshheading:18620949-Proportional Hazards Models,
pubmed-meshheading:18620949-Recombinant Proteins
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
|
|
pubmed:affiliation |
Erasmus University Medical Center, Rotterdam, Netherlands. a.m.m.eggermont@erasmusmc.nl
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
